Compare OLP & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLP | VSTM |
|---|---|---|
| Founded | 1982 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 508.4M | 470.7M |
| IPO Year | 1995 | 2011 |
| Metric | OLP | VSTM |
|---|---|---|
| Price | $22.22 | $5.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $27.50 | $15.25 |
| AVG Volume (30 Days) | 78.3K | ★ 2.1M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 8.17% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $82,740,000.00 | $30,914,000.00 |
| Revenue This Year | $11.98 | $282.64 |
| Revenue Next Year | $3.71 | $72.25 |
| P/E Ratio | $19.15 | ★ N/A |
| Revenue Growth | 1.02 | ★ 209.14 |
| 52 Week Low | $19.62 | $4.01 |
| 52 Week High | $25.90 | $11.25 |
| Indicator | OLP | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 48.37 | 46.16 |
| Support Level | $21.61 | $4.80 |
| Resistance Level | $22.30 | $6.79 |
| Average True Range (ATR) | 0.50 | 0.40 |
| MACD | -0.04 | 0.04 |
| Stochastic Oscillator | 50.79 | 51.49 |
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.